LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy

Traws Pharma (NASDAQ:TRAW) was upgraded by investment analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Friday,Zacks.com reports.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Traws Pharma from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Zacks Research raised Traws Pharma to a “hold” rating in a research report on Thursday, December 4th. HC Wainwright initiated coverage on Traws Pharma in a report on Wednesday, December 3rd. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Traws Pharma Stock Performance

NASDAQ TRAW opened at $2.11 on Friday. The firm’s 50 day moving average price is $1.91 and its 200-day moving average price is $1.95. The company has a market cap of $16.86 million, a PE ratio of 0.02 and a beta of 1.66. Traws Pharma has a 52-week low of $0.97 and a 52-week high of $8.61.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Thursday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Hedge Funds Weigh In On Traws Pharma

An institutional investor recently raised its position in Traws Pharma stock. Two Sigma Investments LP grew its holdings in Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,018 shares of the company’s stock after buying an additional 5,955 shares during the period. Two Sigma Investments LP owned 0.31% of Traws Pharma worth $41,000 as of its most recent filing with the Securities & Exchange Commission. 7.95% of the stock is currently owned by institutional investors and hedge funds.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.